Literature DB >> 28012971

Effects of a human recombinant alkaline phosphatase during impaired mitochondrial function in human renal proximal tubule epithelial cells.

Esther Peters1, Tom Schirris2, Alexander H van Asbeck3, Jelle Gerretsen4, Jennifer Eymael5, Angel Ashikov6, Merel J W Adjobo-Hermans7, Frans Russel8, Peter Pickkers9, Rosalinde Masereeuw10.   

Abstract

Sepsis-associated acute kidney injury is a multifactorial syndrome in which inflammation and renal microcirculatory dysfunction play a profound role. Subsequently, renal tubule mitochondria reprioritize cellular functions to prevent further damage. Here, we investigated the putative protective effects of human recombinant alkaline phosphatase (recAP) during inhibition of mitochondrial respiration in conditionally immortalized human proximal tubule epithelial cells (ciPTEC). Full inhibition of mitochondrial oxygen consumption was obtained after 24h antimycin A treatment, which did not affect cell viability. While recAP did not affect the antimycin A-induced decreased oxygen consumption and increased hypoxia-inducible factor-1α or adrenomedullin gene expression levels, the antimycin A-induced increase of pro-inflammatory cytokines IL-6 and IL-8 was attenuated. Antimycin A tended to induce the release of detrimental purines ATP and ADP, which reached statistical significance when antimycin A was co-incubated with lipopolysaccharide, and were completely converted into cytoprotective adenosine by recAP. As the adenosine A2A receptor was up-regulated after antimycin A exposure, an adenosine A2A receptor knockout ciPTEC cell line was generated in which recAP still provided protection. Together, recAP did not affect oxygen consumption but attenuated the inflammatory response during impaired mitochondrial function, an effect suggested to be mediated by dephosphorylating ATP and ADP into adenosine.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenosine; Antimycin A (PubChem CID: 16218979); Human recombinant alkaline phosphatase; Inflammation; Lipopolysaccharide (PubChem CID: 11970143); Mitochondria; Myxothiazol (PubChem CID: 6437357); Proximal tubule epithelial cells; Respiratory inhibition

Mesh:

Substances:

Year:  2016        PMID: 28012971     DOI: 10.1016/j.ejphar.2016.12.034

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Human recombinant alkaline phosphatase: a promising, yet-to-be-tested agent for the treatment sepsis-induced acute kidney injury.

Authors:  Zhongheng Zhang
Journal:  Ann Transl Med       Date:  2018-12

Review 2.  Targeting the Intestinal Barrier to Prevent Gut-Derived Inflammation and Disease: A Role for Intestinal Alkaline Phosphatase.

Authors:  Florian Kühn; Ruifeng Duan; Matthias Ilmer; Ulrich Wirth; Fatemeh Adiliaghdam; Tobias S Schiergens; Joachim Andrassy; Alexandr V Bazhin; Jens Werner
Journal:  Visc Med       Date:  2021-04-29

Review 3.  Alkaline phosphatase: a potential biomarker for stroke and implications for treatment.

Authors:  Allison L Brichacek; Candice M Brown
Journal:  Metab Brain Dis       Date:  2018-10-04       Impact factor: 3.584

4.  Human Recombinant Alkaline Phosphatase (Ilofotase Alfa) Protects Against Kidney Ischemia-Reperfusion Injury in Mice and Rats Through Adenosine Receptors.

Authors:  Diane L Rosin; J Perry Hall; Shuqiu Zheng; Liping Huang; Silvia Campos-Bilderback; Ruben Sandoval; Andrea Bree; Kevin Beaumont; Emily Miller; Jennifer Larsen; Ghazal Hariri; Neelu Kaila; Iain M Encarnacion; Jeremy D Gale; Andrea van Elsas; Bruce A Molitoris; Mark D Okusa
Journal:  Front Med (Lausanne)       Date:  2022-07-28

5.  Recombinant Alkaline Phosphatase Prevents Acute on Chronic Liver Failure.

Authors:  Cornelius Engelmann; Danielle Adebayo; Marc Oria; Francesco De Chiara; Simone Novelli; Abeba Habtesion; Nathan Davies; Fausto Andreola; Rajiv Jalan
Journal:  Sci Rep       Date:  2020-01-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.